Literature DB >> 19442781

Uterine artery embolization to treat hemorrhage following second-trimester abortion by dilatation and surgical evacuation.

Lisa Haddad1, Laurent Delli-Bovi.   

Abstract

BACKGROUND: This study was conducted to review cases of second-trimester postabortal hemorrhage (PAH) occurring at a private women's health facility that were treated with uterine artery embolization (UAE).
METHODS: A retrospective review was conducted on all second-trimester terminations performed at a private women's health facility between 1999 and 2006. Cases of PAH treated with UAE were reviewed in detail, reviewing progress, operative and discharge notes along with anesthesia records.
RESULTS: Fifteen cases of PAH were identified among 3936 second-trimester terminations that were performed. Seven cases were identified in which UAE was used to treat PAH. Etiologies leading to hemorrhage varied in the seven cases as did the presence of coexisting factors such as infection and anatomic lesions. All cases were successfully treated by UAE, requiring no additional surgical intervention.
CONCLUSION: Given the success of embolization, we offer this as an alternative to exploratory surgery and hysterectomy and as a first-line approach in cases of PAH after conservative management strategies have failed.

Entities:  

Mesh:

Year:  2009        PMID: 19442781     DOI: 10.1016/j.contraception.2008.11.020

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Uterine artery embolization for hemorrhage resulting from second-trimester abortion in women with scarred uterus: report of two cases.

Authors:  Yunfeng Shen; Yumei Liao; Guangsen Feng; Xiaoli Gu; Shi Wan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Efficacy of Prophylactic Uterine Artery Embolization before Obstetrical Procedures with High Risk for Massive Bleeding.

Authors:  Heung Kyu Ko; Ji Hoon Shin; Gi Young Ko; Dong Il Gwon; Jin Hyung Kim; Kichang Han; Shin-Wha Lee
Journal:  Korean J Radiol       Date:  2017-02-07       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.